DAVID GAMBLE: Open Payments
NPI 1033423249 · SALT LAKE CITY, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$169,516 in 433 payments from 17 companies in 2025. Trend: 2023 $166,511 · 2024 $193,820 · 2025 $169,516
Speaker / faculty: $129,861Travel & lodging: $29,375Food & beverage: $5,399Speaker / faculty: $4,881
| Company | Payments | Amount |
|---|---|---|
| Corcept Therapeutics | 128 | $82,008 |
| Lilly USA, LLC | 257 | $74,387 |
| Novo Nordisk Inc | 8 | $6,146 |
| Abbott Laboratories | 16 | $5,137 |
| ABBVIE INC. | 4 | $1,426 |
| Amgen Inc. | 5 | $104 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $78 |
| Xeris Pharmaceuticals, Inc. | 3 | $66 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $23 |
| Novartis Pharmaceuticals Corporation | 1 | $21 |
Products named: Korlym, Ozempic, FREESTYLE LIBRE 3, MOUNJARO, SYNTHROID, Kerendia, REPATHA, RECORLEV.
Industry payments across UT — which companies pay providers there.
